logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Biogen Inc. completes acquisition of Human Immunology Biosciences (HI-Bio™) to strengthen immunology portfolio

Jul 07, 2024•over 1 year ago

Acquiring Company

Biogen

Acquired Company

HI-Bio

CambridgeSan FranciscoBiotechnologyBiotechnology Research

Description

Biogen Inc. has successfully finalized the acquisition of Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company with a focus on targeted therapies for severe immune-mediated diseases. This strategic acquisition strengthens Biogen's immunology portfolio and expands its capability to deliver innovative treatments to patients with unmet medical needs.

Company Information

Company

Biogen

Location

Cambridge, Massachusetts, United States

About

Biogen is a leading biotechnology company, founded in 1978, that pioneers innovative science to deliver new medicines transforming patients’ lives while creating value for shareholders and communities. With deep expertise in human biology and a multi-modal approach, we advance first-in-class therapies that deliver superior outcomes. Guided by bold yet strategic decision-making and a commitment to long-term growth, Biogen continues to push the boundaries of biotechnology.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed